Abstract
Over the last decade, methicillin-resistant Staphylococcus aureus (MRSA) strains have emerged as serious pathogens in the nosocomial and community setting. Hospitalization costs associated with MRSA infections are substantially greater than those associated with methicillin-sensitive S. aureus (MSSA) infections, and MRSA has wider economic effects that involve indirect costs to the patient and to society. In addition, there is some evidence suggesting that MRSA infections increase morbidity and the risk of mortality. Glycopeptides are the backbone antibiotics for the treatment of MRSA infections. However, several recent reports have highlighted the limitations of vancomycin, and its role in the management of serious infections is now being reconsidered. Several new antimicrobials demonstrate in vitro activity against MRSA and other Gram-positive bacteria. Data from large surveys indicate that linezolid, daptomycin, and tigecycline are almost universally active against MRSA. This review will briefly discuss the epidemiology, costs, outcome, and therapeutic options for the management of MRSA infections.
| Original language | English |
|---|---|
| Journal | International Journal of Infectious Diseases |
| Volume | 14 |
| Issue number | SUPPL. 4 |
| DOIs | |
| Publication status | Published - Oct 2010 |
Fingerprint
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
Cite this
Methicillin-resistant Staphylococcus aureus : the superbug. / Ippolito, Giuseppe; Leone, Sebastiano; Lauria, Francesco N.; Nicastri, Emanuele; Wenzel, Richard P.
In: International Journal of Infectious Diseases, Vol. 14, No. SUPPL. 4, 10.2010.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Methicillin-resistant Staphylococcus aureus
T2 - the superbug
AU - Ippolito, Giuseppe
AU - Leone, Sebastiano
AU - Lauria, Francesco N.
AU - Nicastri, Emanuele
AU - Wenzel, Richard P.
PY - 2010/10
Y1 - 2010/10
N2 - Over the last decade, methicillin-resistant Staphylococcus aureus (MRSA) strains have emerged as serious pathogens in the nosocomial and community setting. Hospitalization costs associated with MRSA infections are substantially greater than those associated with methicillin-sensitive S. aureus (MSSA) infections, and MRSA has wider economic effects that involve indirect costs to the patient and to society. In addition, there is some evidence suggesting that MRSA infections increase morbidity and the risk of mortality. Glycopeptides are the backbone antibiotics for the treatment of MRSA infections. However, several recent reports have highlighted the limitations of vancomycin, and its role in the management of serious infections is now being reconsidered. Several new antimicrobials demonstrate in vitro activity against MRSA and other Gram-positive bacteria. Data from large surveys indicate that linezolid, daptomycin, and tigecycline are almost universally active against MRSA. This review will briefly discuss the epidemiology, costs, outcome, and therapeutic options for the management of MRSA infections.
AB - Over the last decade, methicillin-resistant Staphylococcus aureus (MRSA) strains have emerged as serious pathogens in the nosocomial and community setting. Hospitalization costs associated with MRSA infections are substantially greater than those associated with methicillin-sensitive S. aureus (MSSA) infections, and MRSA has wider economic effects that involve indirect costs to the patient and to society. In addition, there is some evidence suggesting that MRSA infections increase morbidity and the risk of mortality. Glycopeptides are the backbone antibiotics for the treatment of MRSA infections. However, several recent reports have highlighted the limitations of vancomycin, and its role in the management of serious infections is now being reconsidered. Several new antimicrobials demonstrate in vitro activity against MRSA and other Gram-positive bacteria. Data from large surveys indicate that linezolid, daptomycin, and tigecycline are almost universally active against MRSA. This review will briefly discuss the epidemiology, costs, outcome, and therapeutic options for the management of MRSA infections.
UR - http://www.scopus.com/inward/record.url?scp=78149280829&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78149280829&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2010.05.003
DO - 10.1016/j.ijid.2010.05.003
M3 - Article
C2 - 20851011
AN - SCOPUS:78149280829
VL - 14
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
SN - 1201-9712
IS - SUPPL. 4
ER -